> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Lantern Pharma Gets Orphan Status LP-184
- URL: https://www.fdaweb.com/lantern-pharma-gets-orphan-status-lp-184/
- Published: 2021-08-30T12:00:00.000Z
- Updated: 2026-09-14T17:12:23.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5150043

**FDA has granted Lantern Pharma** an orphan drug designation for LP-184 and its use in treating glioblastoma multiforme (GBM) and other malignant gliomas. LP-184 is a small molecule drug candidate and next generation alkylating agent that “preferentially damages DNA in cancer cells that over-express certain biomarkers or that harbor mutations in DNA repair pathways,” the company says.

“We recently reported [positive preclinical data](https://c212.net/c/link/?t=0&l=en&o=3274056-1&h=4090440243&u=https%3A%2F%2Fir.lanternpharma.com%2Fnews%2Fpress-releases%2Fdetail%2F58%2Flantern-pharma-announces-positive-preclinical-data-in&a=positive+preclinical+data&ref=fdaweb.com) that demonstrated LP-184 inhibits tumor growth by greater than 106% and improved survival in animal models of GBM,” the company says. “We believe LP-184’s ability to cross the blood-brain barrier, together with its anti-tumor efficacy and sensitivity correlations with relevant biomarkers, highlight LP-184’s potential to be used as both monotherapy as well as a synergistic agent in combination with other drugs to address the unmet needs in GBM and other aggressive central nervous system tumors.”